PLSH (Panacea Life Sciences Holdings) Current Deferred Revenue: $0.00 Mil (As of Sep. 2025)


PLSH Panacea Life Sciences Holdings Inc PLSH
28 GF Score
Price $0.14
! 6 Warning Signs
View Full Analysis

What is Panacea Life Sciences Holdings Current Deferred Revenue?

Panacea Life Sciences Holdings PLSH +4.55% 28 Current Deferred Revenue is $0.00 Mil as of Sep. 2025. GuruFocus rates PLSH with a GF Score™ of 28/100. The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Panacea Life Sciences Holdings's current deferred revenue for the quarter that ended in Sep. 2025 was $0.00 Mil.

Panacea Life Sciences Holdings Current Deferred Revenue Related Terms

Panacea Life Sciences Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings Current Deferred Revenue Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
0.00 0.00 0.00 0.00

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PLSH
28GF Score
Panacea Life Sciences Holdings Inc PLSH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Panacea Life Sciences Holdings (PLSH) has a Current Deferred Revenue of $0.00 Mil as of Sep. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Panacea Life Sciences Holdings and its competitors.
Is Panacea Life Sciences Holdings' Current Deferred Revenue too high?
Panacea Life Sciences Holdings' current Current Deferred Revenue is $0.00 Mil. Overall, Panacea Life Sciences Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Panacea Life Sciences Holdings' Current Deferred Revenue compare to SKYI and IMCC?
Panacea Life Sciences Holdings' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Panacea Life Sciences Holdings and its competitors. Panacea Life Sciences Holdings's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Panacea Life Sciences Holdings' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Current Deferred Revenue is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
28GF Score

Get the complete analysis for PLSH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price